The Trustees Of The University Of Pennsylvania Patent Portfolio Statistics

The Trustees Of The University Of Pennsylvania

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of The Trustees Of The University Of Pennsylvania look like?

Total Applications: 1,975
Granted Patents: 1,107
Grant Index 72.5 %
Abandoned/Rejected Applications: 420 (27.5%)
In-Process Applications: 442
Average Grant Time: 3.44 Years
Average Office Actions: 2.21

Which Technology Area The Trustees Of The University Of Pennsylvania is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1648 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 118
Opap Parked GAU 118
1633 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 107
1644 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 56
1642 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 55

How many patents are The Trustees Of The University Of Pennsylvania filing every year?

Year Total Applications
2022 0*
2021 81*
2020 98
2019 100
2018 160

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of The Trustees Of The University Of Pennsylvania in USPTO?

Publication number:
Application number: 17/420,252

Abstract:
None

Publication date:
Applicant: The Trustees Of The University Of Pennsylvania
Inventors: Glenn Jeffrey S


Publication number: US20220025408A1
Application number: 17/502,402

Abstract:
In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.

Publication date: 2022-01-27
Applicant: The Trustees Of The University Of Pennsylvania
Inventors: Bak O Rasmus


Publication number: US20220025409A1
Application number: 17/502,421

Abstract:
In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.

Publication date: 2022-01-27
Applicant: The Trustees Of The University Of Pennsylvania
Inventors: Daniel Dever P


How are The Trustees Of The University Of Pennsylvania’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/420,252 Pi4-Kinase Inhibitors With Anti-Cancer Activity Application Undergoing Preexam Processing OPAP Central, Docket
17/502,402 Nuclease-Mediated Genome Editing Of Primary Cells And Related Methods Of Treatment 1632 Noble, Marcia Stephens
17/502,421 Nuclease-Mediated Genome Editing Of Primary Cells 1632 Noble, Marcia Stephens
17/498,901 Muscular Dystrophy Chimeric Cells And Method For Treating Muscular Dystrophies OPAP Central, Docket
17/499,272 Bifunctional Molecules For Lysosomal Targeting And Related Compositions And Methods 1646 Li, Ruixiang